Keywords: cellegy, losses, deepen, sales, gryphon, fall, usa-based
Cellegy losses deepen as sales to Gryphon fall
Article | 25 February 2002
USA-based Cellegy Pharmaceuticals has reported revenues of $877,000 forfull-year 2001, compared with $1.6 million for 2000. Revenues consisted of $660,000 in product sales to Gryphon ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
